A molecular imaging technique using 68Ga-HER2 PET/CT scans can predict pathologic complete response in HER2-positive breast cancer after just two treatment cycles. Researchers reported the prospective findings in the October issue of The Journal of Nuclear Medicine, showing that patients with substantial radiotracer drop achieved an 85 percent complete response rate.
For the approximately one in five women diagnosed with HER2-positive breast tumors, the months leading up to surgery are marked by intense uncertainty. Representing a total of 20 to 25 percent of all breast cancer diagnoses, HER2-positive tumors stand among the most severe variants of the condition, carrying less favorable prognoses when left without effective treatment. Neoadjuvant therapy administered before operations can shrink these aggressive cancers, and in some patients eliminates them entirely, yet oncologists have lacked a reliable way to gauge success early in the course of treatment.
How 68Ga-HER2 PET/CT Scans Track Early Biological Shifts
Unlike anatomical imaging that measures only physical size, molecular imaging tracks biological activity, capturing how much of the HER2 target is present and accessible. When drug treatment works, HER2 expression and tumor metabolism shift before the mass physically shrinks. As a novel molecular imaging tool, 68Ga-HER2 PET/CT has recently gained recognition for enabling noninvasive, whole-body mapping of HER2 presence.
To evaluate this technique, investigators launched a prospective trial designed to measure how effectively 68Ga-HER2 PET/CT forecasts pathologic response to neoadjuvant treatment among individuals suffering from HER2-positive breast cancer. Every participant received at least four cycles of neoadjuvant therapy followed by surgery, with 68Ga-HER2 PET/CT scans performed at baseline, after the second treatment cycle, and immediately before surgery.
The 61 Percent Uptake-Reduction Threshold and Surgical Outcomes
Patients whose primary tumor tracer uptake decreased by at least 61 percent after the second treatment cycle achieved an 85 percent rate of pathologic complete response at surgery. By contrast, patients whose tracer uptake dropped by less than that threshold experienced just a 38 percent complete response rate.
| Tracer Uptake Reduction | Patient Count | Pathologic Complete Response Rate |
|---|---|---|
| At least 61 percent reduction | 44 total study patients | 85 percent |
| Less than 61 percent reduction | 44 total study patients | 38 percent |
Preoperative imaging demonstrated further reduction in the lesion size to approximately 2.0 by 0.6 centimeters, with no abnormal tracer uptake detected.
These findings provide preliminary prospective evidence that changes in HER2-targeted tracer uptake can predict treatment response at a very early stage.
Xinming Zhao, MD, PhD, director of the Department of Nuclear Medicine at the Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital
Why Traditional Monitoring Methods Fall Short
Current monitoring modalities each present distinct limitations for clinical teams managing pre-surgical drug regimens. Yunjiang Liu outlined the persistent difficulties across standard evaluation techniques.
Ultrasound offers cost-effective assessment of lymph nodes but is operator-dependent; mammography detects calcifications well but poorly measures tumor size; MRI, the standard neoadjuvant therapy monitoring modality, faces challenges in differentiating between fibrosis and tumors; and clinical examination, although rapid, lacks accuracy.
Yunjiang Liu, MD, PhD, professor at the Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital in Shijiazhuang, China
Next Steps and Clinical Implications for Future Trials
Performing 68Ga-HER2 PET/CT scans early on could help spot patients unlikely to benefit from neoadjuvant therapy, opening the door to prompt evaluations of alternative medical protocols or surgical interventions. Pointing to future research, the team noted: If future studies confirm our findings, imaging could provide earlier information to support discussions about alternative treatment strategies or surgical timing.
The authors of the prospective study include Sinuo Gao, Chao Shi, Xindi Ma, and Yunjiang Liu from the Department of Breast Center at the Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital in Shijiazhuang, China, alongside Zhaoqi Zhang and Xinming Zhao from the Department of Nuclear Medicine at the same institutions.
Despite the encouraging nature of these preliminary prospective results, the investigators pointed out that the research faced constraints due to a limited participant count, a single-center framework, and diverse neoadjuvant treatment protocols. Larger, multicenter investigations remain necessary to validate these findings and determine whether early molecular imaging can fundamentally alter treatment pathways for patients facing aggressive breast cancer.